机译:吉非替尼治疗的ER + sup> HER-2过表达的MCF-7乳腺癌肿瘤中低氧细胞水平降低与mTOR通路过度活化有关:雷帕霉素联合治疗的治疗意义
Department of Advanced Therapeutics British Columbia Cancer Agency 675 West 10th Ave. Vancouver BC Canada V5Z 1L3;
Department of Advanced Therapeutics British Columbia Cancer Agency 675 West 10th Ave. Vancouver BC Canada V5Z 1L3;
Department of Advanced Therapeutics British Columbia Cancer Agency 675 West 10th Ave. Vancouver BC Canada V5Z 1L3;
Department of Advanced Therapeutics British Columbia Cancer Agency 675 West 10th Ave. Vancouver BC Canada V5Z 1L3;
Department of Advanced Therapeutics British Columbia Cancer Agency 675 West 10th Ave. Vancouver BC Canada V5Z 1L3;
Department of Advanced Therapeutics British Columbia Cancer Agency 675 West 10th Ave. Vancouver BC Canada V5Z 1L3;
Department of Medical Biophysics British Columbia Cancer Research Centre Vancouver BC Canada;
Department of Medical Biophysics British Columbia Cancer Research Centre Vancouver BC Canada;
Medical Oncology British Columbia Cancer Agency Vancouver BC Canada;
Department of Advanced Therapeutics British Columbia Cancer Agency 675 West 10th Ave. Vancouver BC Canada V5Z 1L3;
Breast cancer; Gefitinib; HER-2; mTOR; Tumor microenvironment;
机译:吉非替尼治疗的过表达ER(+)HER-2的MCF-7乳腺癌肿瘤中低氧细胞水平的降低与mTOR途径的过度活化有关:雷帕霉素联合治疗的治疗意义。
机译:在过表达HER-2的乳腺癌细胞中靶向YB-1可通过mTOR / STAT3途径诱导凋亡,并抑制小鼠的肿瘤生长。
机译:吉非替尼和RAD001的组合抑制过表达HER2的乳腺癌细胞和肿瘤的生长,无论曲妥珠单抗敏感性如何
机译:MRTF-A降低他莫昔芬对MCF-7人乳腺癌细胞的抗肿瘤作用
机译:通过激活PI3K / PDK / Akt信号转导途径,MCF-7乳腺癌细胞对抗癌药物的敏感性降低。
机译:依维莫司通过抑制雷帕霉素(mTOR)途径的磷脂酰肌醇3-激酶(PI3K)/ Akt /哺乳动物靶标逆转ER +人乳腺癌细胞中的palbociclib耐药性。
机译:用曲妥珠单抗(Herceptin)和Gefitinib(ZD1839)治疗Her-2 / Neu过表达乳腺癌异种癌模型:药物组合对肿瘤生长,Her-2 / Neu和表皮生长因子受体表达,以及可行的缺氧细胞级分
机译:评估和治疗肿瘤过度表达HER-2 / neu的晚期乳腺癌患者的新方法